Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse
- PMID: 24682777
- PMCID: PMC4125810
- DOI: 10.1007/s11011-014-9534-3
Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse
Erratum in
- Metab Brain Dis. 2014 Sep;29(3):671
Abstract
Accumulating evidence indicates that elevated homocysteine (Hcy) level occurs in first-episode schizophrenia (FES) patients. We included 56 FES patients and 53 healthy controls (HC). Plasma level of Hcy was significantly higher in FES patients than HC (p = 0.044). In addition, plasma levels of high-density lipoproteins (HDL) and folate were significantly lower in FES than in HC (p < 0.001). Positive family history of schizophrenia was associated with lower plasma HDL (p = 0.041) and vitamin B12 (p = 0.017), as well as higher level of Hcy (p = 0.017). Patients with FES, who abused cannabis, had higher levels of Hcy (p = 0.017), as well as lower levels of vitamin B12 (p = 0.017) and HDL (p = 0.041). Plasma Hcy negatively correlated with duration of untreated psychosis (r = -0.272, p = 0.042). There was a positive correlation between Hcy level and the severity of negative symptoms (r = 0.363, p = 0.006) and general psychopathology (r = 0.349, p = 0.008) assessed using Positive and Negative Syndrome Scale (PANSS). Vitamin B12 level was negatively associated with the severity of negative symptoms (r = -0.406, p = 0.002), while folate level negatively correlated with general psychopathology score (r = -0.365, p = 0.006) in PANSS. These results indicate that the severity of one-carbon metabolism alterations and HDL deficiency might be associated with family history of schizophrenia and cannabis abuse. Lower vitamin B12 and folate along with elevated Hcy may influence the severity of FES psychopathology.
References
-
- Ayesa-Arriola R, Perez-Iglesias R, Rodriguez-Sanchez JM, Mata I, Gomez-Ruiz E, Garcia-Unzueta M, Martinez-Garcia O, Tabares-Seisdedos R, Vazquez-Barquero JL, Crespo-Facorro B. Homocysteine and cognition in first-episode psychosis patients. Eur Arch Psychiatry Clin Neurosci. 2012;262(7):557–564. doi: 10.1007/s00406-012-0302-2. - DOI - PubMed
-
- Bahorik AL, Newhill CE, Queen CC, Eack SM (2013) Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychol Med 1–9. doi:10.1017/S0033291713000548 - PubMed
-
- Bicikova M, Hampl R, Hill M, Ripova D, Mohr P, Putz Z. Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuroendocrinol Lett. 2011;32(2):141–147. - PubMed
-
- Bouaziz N, Ayedi I, Sidhom O, Kallel A, Rafrafi R, Jomaa R, Melki W, Feki M, Kaabechi N, El Hechmi Z. Plasma homocysteine in schizophrenia: determinants and clinical correlations in Tunisian patients free from antipsychotics. Psychiatry Res. 2010;179(1):24–29. doi: 10.1016/j.psychres.2010.04.008. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
